Education
About Us
Working with TipRanks
Follow Us
NeuroPace (NPCE)
NASDAQ:NPCE
NPCE Analyst Ratings
Strong Buy
6 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
NPCE Stock 12 Month Forecast
Average Price Target
$17.80
▲(42.86%Upside)
| Highest Price Target$20.00 | Average Price Target$17.80 | Lowest Price Target$16.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
TipRanks
$12.5
Hold
0.32%
Upside
Reiterated
05/29/25
Lake Street
$20
Buy
60.51%
Upside
Reiterated
05/28/25
H.C. Wainwright
$18
Buy
44.46%
Upside
Initiated
05/28/25
Leerink Partners
$18
Buy
44.46%
Upside
Reiterated
05/27/25
Wells Fargo
$17
Buy
36.44%
Upside
Reiterated
05/27/25
J.P. Morgan
―
Buy
―
Reiterated
05/27/25
Cantor Fitzgerald
$17→$16
Buy
28.41%
Upside
Reiterated
05/27/25
UBS
$17
Buy
36.44%
Upside
Initiated
01/21/25
Sustainable DD We initiate coverage of NPCE with a Buy rating and $17 PT. We view NPCE's RNS (responsive neuromodulation system) technology as providing a differentiated, and clinically proven interventional solution to address the vastly undertreated and underpenetrated DRE (drug resistant epilepsy) market. Ultimately, we believe NPCE shares should see multiple expansion over the next twelve months as the company is on the verge of TAM expanding catalysts in the 2H25 timeframe that we believe should drive a growth inflection. Our above consensus ~22% top-line CAGR (vs.
Morgan Stanley
$8
Hold
-35.79%
Downside
Reiterated
11/13/24
Wolfe Research
$16→$14
Buy
12.36%
Upside
Reiterated
08/14/24
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
TipRanks
$12.5
Hold
0.32%
Upside
Reiterated
05/29/25
Lake Street
$20
Buy
60.51%
Upside
Reiterated
05/28/25
H.C. Wainwright
$18
Buy
44.46%
Upside
Initiated
05/28/25
Leerink Partners
$18
Buy
44.46%
Upside
Reiterated
05/27/25
Wells Fargo
$17
Buy
36.44%
Upside
Reiterated
05/27/25
J.P. Morgan
―
Buy
―
Reiterated
05/27/25
Cantor Fitzgerald
$17→$16
Buy
28.41%
Upside
Reiterated
05/27/25
UBS
$17
Buy
36.44%
Upside
Initiated
01/21/25
Sustainable DD We initiate coverage of NPCE with a Buy rating and $17 PT. We view NPCE's RNS (responsive neuromodulation system) technology as providing a differentiated, and clinically proven interventional solution to address the vastly undertreated and underpenetrated DRE (drug resistant epilepsy) market. Ultimately, we believe NPCE shares should see multiple expansion over the next twelve months as the company is on the verge of TAM expanding catalysts in the 2H25 timeframe that we believe should drive a growth inflection. Our above consensus ~22% top-line CAGR (vs.
Morgan Stanley
$8
Hold
-35.79%
Downside
Reiterated
11/13/24
Wolfe Research
$16→$14
Buy
12.36%
Upside
Reiterated
08/14/24
Best Analysts Covering NeuroPace
1 Month
xxx
Success Rate
16/22 ratings generated profit
Average Return
+9.57%
reiterated a xxx
rating 3 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 72.73% of your transactions generating a profit, with an average return of +9.57% per trade.
3 Months
xxx
Success Rate
16/22 ratings generated profit
Average Return
+29.87%
reiterated a xxx
rating 3 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 72.73% of your transactions generating a profit, with an average return of +29.87% per trade.
1 Year
Success Rate
17/22 ratings generated profit
Average Return
+55.21%
reiterated a buy rating 3 days ago
Copying Frank Takkinen's trades and holding each position for 1 Year would result in 77.27% of your transactions generating a profit, with an average return of +55.21% per trade.
2 Years
xxx
Success Rate
18/22 ratings generated profit
Average Return
+79.84%
reiterated a xxx
rating 3 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 81.82% of your transactions generating a profit, with an average return of +79.84% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
NPCE Analyst Recommendation Trends
Rating
Jan 25
Feb 25
Mar 25
Apr 25
May 25
Strong Buy
7
5
7
11
12
Buy
11
10
10
4
14
Hold
1
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
19
15
17
15
26
Each month's total comprises the sum of three months' worth of ratings.
NPCE Financial Forecast
NPCE Stock Forecast FAQ
What is NPCE’s average 12-month price target, according to analysts?
Based on analyst ratings, NeuroPace’s 12-month average price target is 17.80.
What is NPCE’s upside potential, based on the analysts’ average price target?
NeuroPace has 42.86% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is NPCE a Buy, Sell or Hold?
NeuroPace has a consensus rating of Strong Buy which is based on 6 buy ratings, 0 hold ratings and 0 sell ratings.
What is NeuroPace’s price target?
The average price target for NeuroPace is 17.80. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $20.00 ,the lowest forecast is $16.00. The average price target represents 42.86% Increase from the current price of $12.46.
The highest analyst price target is $20.00 ,the lowest forecast is $16.00. The average price target represents 42.86% Increase from the current price of $12.46.
What do analysts say about NeuroPace?
NeuroPace’s analyst rating consensus is a Strong Buy. This is based on the ratings of 6 Wall Streets Analysts.
How can I buy shares of NPCE?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.